row_id	original_smiles	source_caption	target_caption	gt_smiles	pred_smiles
0	O=C(N1CCCC1)N1Cc2c(-c3ccc(F)cc3)ncn2-c2ccccc21	This molecule has the following properties: Lipinski compliant; very high CYP2C9 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP2C9 inhibition liability.	O=C(N1CCCC1)N1Cc2c(-c3ccc(F)cc3)ncn2-c2cccc(F)c21	O=C(N1CCCC1)N1Cc2c(-c3ccccc3)ncn2-c2ccccc21
1	CN(C)C(=O)N1c2ccccc2-n2cnc(-c3ccccc3)c2C1(C)C	This molecule has the following properties: Lipinski compliant; high AMES risk.	This molecule has the following properties: Lipinski compliant; reduced AMES risk.	CN(C)C(=O)N1c2ccccc2-n2cnc(-c3ccc(F)cc3)c2C1(C)C	CN(C)C(=O)N1c2ccccc2-n2cnc(-c3ccc(F)cc3)c2C1(C)C
2	CC(C)OC(=O)N1Cc2c(-c3ccc(F)cc3)ncn2-c2ccccc21	This molecule has the following properties: Lipinski compliant; very high P-gp inhibition.	This molecule has the following properties: Lipinski compliant; reduced P-gp inhibition.	FC1=CC=C(C2=NC(CNC(=O)OC(C)C)=NC3=C2C=CC=C3)C=C1	CC(C)OC(=O)N1Cc2c(-c3cccClcc3)ncn2-c2ccccc21
3	CCOC(=O)c1c2c(ncn2-c2ccc(F)cc2)n(C)c1-c1cccc(Cl)c1	This molecule has the following properties: Lipinski compliant; very high P-gp inhibition.	This molecule has the following properties: Lipinski compliant; reduced P-gp inhibition.	CC(C)n1c(=O)c2c(-c3ccc(F)cc3)ncn2c2cccc(Cl)c21	CCOC(=O)c1c2c(ncn2-c2ccc(F)cc2)n(C)c1-c1ccccHc1
4	C[C@@H]1CN(C(=O)N2Cc3c(C(=O)OC(C)(C)C)ncn3-c3ccc(Cl)cc32)C[C@H](C)N1	This molecule has the following properties: Lipinski compliant; very high CYP1A2 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP1A2 inhibition liability.	C[C@@H]1CN(C(=O)N2Cc3c(C(=O)OC(C)(C)C)ncn3-c3ccc(F)cc32)C[C@H](C)N1	C[C@@H]1CN(C(=O)N2Cc3c(C(=O)OC(C)(C)C)ncn3-c3ccccc32)C[C@H](C)N1
5	Cc1ccc2oc(-c3ccccc3)cc(=O)c2c1	This molecule has the following properties: Lipinski compliant; high CYP3A4 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP3A4 inhibition liability.	CC(C)c1ccc2oc(-c3ccccc3)cc(=O)c2c1	Cc1ccc2oc(-c3ccc(F)cc3)cc(=O)c2c1
6	CCCC(=O)c1cccc(-c2cc(=O)c3cc(C)ccc3o2)c1	This molecule has the following properties: Lipinski compliant; very high CYP1A2 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP1A2 inhibition liability.	CCCCOc1cccc(-c2cc(=O)c3cc(C)ccc3o2)c1	CCCC(=O)c1cccc(-c2cc(=O)c3cc(C)ccc3[nH]2)c1
7	N#CC1CCCN1C(=O)N1Cc2c(-c3ccccc3)ncn2-c2ccccc21	This molecule has the following properties: Lipinski compliant; high DILI risk.	This molecule has the following properties: Lipinski compliant; reduced DILI risk.	O=C(N1CCCC1)N1Cc2c(-c3ccccc3)ncn2-c2ccccc21	N#CC1CCCN1C(=O)N1Cc2c(-c3ccccc3)ncn2-c2cccs21
8	CC(C)(C)c1nc2ccccc2n1Cc1ccc(C)cc1	This molecule has the following properties: Lipinski compliant; moderate AMES risk.	This molecule has the following properties: Lipinski compliant; reduced AMES risk.	Cc1ccc(-c2ncn3c2C(C)(C)N(C(=O)N2CCCC2)c2ccccc2-3)cc1	CC(C)(C)c1nc2ccccc2n1Cc1ccccc1
9	C[C@@H]1CN(C(=O)N2Cc3c(C(=O)OC(C)(C)C)ncn3-c3ccccc32)C[C@H](C)N1C	This molecule has the following properties: Lipinski compliant; very high CYP1A2 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP1A2 inhibition liability.	O=C(N1CC[C@H](N(C)C)C1)N1CC2=C(N=CN2C(=O)OC(C)(C)C)C2=CC=CC=C12	C[C@@H]1CN(C(=O)N2Cc3c(C(=O)OC(C)(C)C)ncn3-c3ccc(F)cc32)C[C@H](C)N1C
10	CC1CCC2C(C1)N(C(=O)N1CC(C)N(C)C(C)C1)Cc1c(C(=O)OC(C)(C)C)ncn1-2	This molecule has the following properties: Lipinski compliant; very high CYP2C9 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP2C9 inhibition liability.	Cc1ccc2c(c1)N(C(=O)N1C[C@@H](C)N(C)[C@@H](C)C1)Cc1c(C(=O)OC(C)(C)C)ncn1-2	CC1CCC2C(C1)N(C(=O)N1CC(C)N(C)C(C)C1)Cc1c(C(=O)OC)ncn1-2
11	CC(C)(C)C1CS(=O)(=O)C(c2ccc(F)cc2)S(=O)(=O)C1	This molecule has the following properties: Lipinski compliant; high P-gp inhibition.	This molecule has the following properties: Lipinski compliant; reduced P-gp inhibition.	C[C](C)(C)C1CS(=O)(=O)C(c2ccc(Cl)cc2)S(=O)(=O)C1	CC(C)(C)C1CS(=O)(=O)C(c2cccClcc2)S(=O)(=O)C1
12	CNC1=CC=C(C=C1)C(=O)N[C@H](CS(=O)(=O)C2CCCCC2)C(=O)O	This molecule has the following properties: Lipinski compliant; high DILI risk.	This molecule has the following properties: Lipinski compliant; reduced DILI risk.	CC(C)(C)[C@H]1CS(=O)(=O)[C@@](C)(c2ccc(C#N)cc2)S(=O)(=O)C1	CNC1=CC=C(C=C1)C(=O)N[C@H](CS(=O)(=O)C2CCCCC2)C(=O)NC(=O)C3CC3
13	CNC(=O)c1ccc([C@](C)(S(=O)(=O)C2CS(=O)(=O)[C@@](C)(NC)C2)c3ccccc3)cc1	This molecule has the following properties: Lipinski compliant; high hepatotoxicity risk.	This molecule has the following properties: Lipinski compliant; reduced hepatotoxicity risk.	CC(C)(C)[C@H]1CS(=O)(=O)[C@@](C)(c2ccc(C#N)cc2)S(=O)(=O)C1	CNC(=O)c1ccc([C@](C)(S(=O)(=O)C2CS(=O)(=O)[C@H](C)(NC)C2)c3ccccc3)cc1
14	C#Cc1ccc(C2SCC(C(C)(C)C)CS2)cc1	This molecule has the following properties: Lipinski compliant; moderate hERG liability.	This molecule has the following properties: Lipinski compliant; lower hERG liability.	C#Cc1ccc(C2SCC(C)(C)CCS2)cc1	C#Cc1ccc(C2SCC(C(C)(C)C)CS2)cc1
15	CC(C)(C)C1CSC(c2ccc(C#N)cc2)SC1	This molecule has the following properties: Lipinski compliant; high P-gp inhibition.	This molecule has the following properties: Lipinski compliant; reduced P-gp inhibition.	C[C@@]1(C)S[C@H](c2ccc(C#N)cc2)S[C@@H]1C	CC(C)(C)C1CSC(c2ccc(Cl)cc2)SC1
16	CCOC1CS(=O)(=O)C(C)(c2ccc(CN)cc2)S(=O)(=O)C1	This molecule has the following properties: Lipinski compliant; very high P-gp inhibition.	This molecule has the following properties: Lipinski compliant; reduced P-gp inhibition.	CC(C)(C)C1CS(=O)(=O)C(C)(c2ccc(C#N)cc2)S(=O)(=O)C1	CCOC1CS(=O)(=O)C(C)(c2ccc(CN)cc2)S(=O)(=O)C1C
17	CC(C)(C)C1CS(=O)(=O)C(C)(c2ccc(I)cc2)S(=O)(=O)C1	This molecule has the following properties: Lipinski compliant; very high CYP2C9 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP2C9 inhibition liability.	C[C@@]1(CS(=O)(=O)C(C)(c2ccc(I)cc2)S(=O)(=O)C1)C	CC(C)(C)C1CS(=O)(=O)C(C)(c2ccccc2)S(=O)(=O)C1
18	CC(=O)c1cc2c3ccccc3n3c(=O)ccc(n1)c23	This molecule has the following properties: Lipinski compliant; moderate P-gp inhibition.	This molecule has the following properties: Lipinski compliant; reduced P-gp inhibition.	COC(=O)c1cc2c3ccccc3n3c(=O)ccc(n1)c23	CC(=O)c1cc2c3ccccc3n3c(=O)ccc(n1)c2[nH]3
19	COC(=O)c1cc2c(cn1)[nH]c1ccccc12	This molecule has the following properties: Lipinski compliant; high CYP2C9 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP2C9 inhibition liability.	CNC(=O)c1cc2c(cn1)[nH]c1ccccc12	COC(=O)c1cc2c(cn1)[nH]c1ccsc12
20	CCOC(=O)c1cc2c3ccccc3nc-2c[nH]1	This molecule has the following properties: Lipinski compliant; very high CYP2C9 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP2C9 inhibition liability.	CC(=O)Nc1cc2c3ccccc3nc-2c[nH]1	CCOC(=O)c1cc2c3ccccc3nc-2s[nH]1
21	CCCCN(CCCC)C(=O)Cc1c(-c2ccc(F)cc2)nc2ccc(F)cn12	This molecule has the following properties: Lipinski compliant; very high CYP3A4 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP3A4 inhibition liability.	CCCCN(CCCC)C(=O)Cc1c(-c2ccc(Cl)cc2)nc2ccc(Cl)cn12	CCCCN(CCCC)C(=O)Cc1c(-c2cccClcc2)nc2cccClcn12
22	CCCCN(C(=O)Cc1c(-c2ccc(Cl)cc2)nc2ccc(Cl)cn12)c1ccccc1	This molecule has the following properties: Lipinski compliant; very high CYP1A2 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP1A2 inhibition liability.	CCCN(C(=O)Cc1c(-c2ccc(Cl)cc2)nc2ccc(F)cn12)c1ccccc1	CCCCN(C(=O)Cc1c(-c2ccc(Cl)cc2)nc2sc(Cl)cn12)c1ccccc1
23	CCOC(=O)C1CCCN(C(=O)Cc2c(-c3ccc(Cl)cc3)nc3ccc(Cl)cn23)C1	This molecule has the following properties: Lipinski compliant; high hERG liability.	This molecule has the following properties: Lipinski compliant; lower hERG liability.	CC(=O)N1CCCN(C(=O)Cc2c(-c3ccc(Cl)cc3)nc3ccc(Cl)cn23)C1	CCOC(=O)C1CCCN(C(=O)Cc2c(-c3cccClcc3)nc3cccClcn23)C1
24	CN1CCN(c2cccc3ccccc23)CC1	This molecule has the following properties: Lipinski compliant; minimal intestinal absorption.	This molecule has the following properties: Lipinski compliant; improved intestinal absorption.	O=C1[C@@H]2CCCN2C(=O)CN1CN1CCN(c2cccc3ccccc23)CC1	CN1CCN(c2cccc3ccccc23)CC1O
25	Oc1noc(C2CNCC2)c1Cc1ccc2ccc(Br)cc2c1	This molecule has the following properties: Lipinski compliant; high DILI risk.	This molecule has the following properties: Lipinski compliant; reduced DILI risk.	Oc1noc(C2CCNCC2)c1Cc1ccc2ccc(Br)cc2c1	Oc1noc(C2CNCC2)c1Cc1ccc2cccClcc2c1
26	Oc1noc(C2CCCNCC2)c1Cc1ccc2c(Br)cccc2c1	This molecule has the following properties: Lipinski compliant; high DILI risk.	This molecule has the following properties: Lipinski compliant; reduced DILI risk.	Oc1noc(C2CCNCC2)c1Cc1ccc2c(Br)cccc2c1	Oc1noc(C2CCCNCC2)c1Cc1ccc2ccc(c2c1)C(F)(F)F
27	Oc1noc(C2CCNCC2)c1Cc1ccc2ccccc2c1	This molecule has the following properties: Lipinski compliant; high DILI risk.	This molecule has the following properties: Lipinski compliant; reduced DILI risk.	Oc1noc(C2CCNCC2)c1Cc1ccc2ccccc2c1F	Oc1noc(C2CCNCC2)c1Cc1ccc2cccccc2c1
28	Oc1noc(C2CCCNCC2)c1Cc1ccc2ccccc2c1Cl	This molecule has the following properties: Lipinski compliant; high DILI risk.	This molecule has the following properties: Lipinski compliant; reduced DILI risk.	Oc1noc(C2CCNCC2)c1Cc1ccc2ccccc2c1Cl	Oc1noc(C2CCCNCC2)c1Cc1ccc2ccccc2c1F
29	CSc1c(Cc2c(O)noc2C2CCNCC2)ccc2ccccc12	This molecule has the following properties: Lipinski compliant; very high CYP1A2 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP1A2 inhibition liability.	CCN1CCCC1c1c(Cc2c(O)noc2C2CCNCC2)ccc2ccccc12	CSc1c(Cc2c(O)noc2C2CCNCC2)ccc2ccccc1Cl
30	Oc1noc(C2CCNCC2)c1Cc1ccc2ccccc2c1	This molecule has the following properties: Lipinski compliant; low AMES risk.	This molecule has the following properties: Lipinski compliant; high AMES risk.	Oc1noc(C2CCNCC2)c1Cc1ccc2ccccc2c1Sc1ccccc1	Oc1noc(C2CCNCC2)c1Cc1ccc2cccnc2c1
31	N#Cc1c(Cc2c(O)noc2C2CCNCC2)ccc2ccccc12	This molecule has the following properties: Lipinski compliant; very high CYP1A2 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP1A2 inhibition liability.	CN1CCN(CC1)c1c(Cc2c(O)noc2C2CCNCC2)ccc2ccccc12	N#Cc1c(Cc2c(O)noc2C2CCNCC2)ccc2ccccc1Cl
32	Oc1noc(C2CNCC2)c1Cc1ccc2ccccc2c1-c1ccccc1	This molecule has the following properties: Lipinski compliant; high DILI risk.	This molecule has the following properties: Lipinski compliant; reduced DILI risk.	Oc1noc(C2CCNCC2)c1Cc1ccc2ccccc2c1-c1ccccc1	Oc1noc(C2CNCC2)c1Cc1ccc2ccccc2c1-c1cccnc1
33	Oc1noc(C2CCNCC2)c1-c1ccccc1	This molecule has the following properties: Lipinski compliant; high DILI risk.	This molecule has the following properties: Lipinski compliant; reduced DILI risk.	Oc1noc(C2CCNCC2)c1-c1ccccc1N	Oc1noc(C2CCNCC2)c1-c1cccs1
34	Oc1noc(C2CCCNCC2)c1-c1ccc2ccccc2c1	This molecule has the following properties: Lipinski compliant; low CYP1A2 inhibition.	This molecule has the following properties: Lipinski compliant; very high CYP1A2 inhibition.	Oc1noc(C2CCNCC2)c1-c1ccc2ccccc2c1	Oc1noc(C2CCCNCC2)c1-c1ccc2ccccc2c1O
35	Oc1noc(C2CCNCC2)c1-c1cccc2ccccc12	This molecule has the following properties: Lipinski compliant; very high CYP1A2 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP1A2 inhibition liability.	O=C1NOC(C2CCNCC2)C1C1=CC=CC2=CC=CC=C12	Oc1noc(C2CCNCC2)c1-c1cccc2cccnc12
36	c1ccc2cc(Cc3cnoc3C3CCNCC3)ccc2c1	This molecule has the following properties: Lipinski compliant; high CYP1A2 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP1A2 inhibition liability.	CCN1CCN(CC1)Cc1cnoc1Cc1ccccc1	c1ccc2cc(Cc3cnoc3C3CCNCC3)ccc2c1
37	O=C(O)CCCN1N=C(C2=CC=C(OC)C=C2)C=C1	This molecule has the following properties: Lipinski compliant; moderate AMES risk.	This molecule has the following properties: Lipinski compliant; reduced AMES risk.	COc1ccc(-c2ccc(=N)n(CCCC(=O)O)n2)cc1	O=C(O)CCCN1N=C(C2=CC=C(C=C2)OC)C=C1
38	Oc1noc(C2CCCNCC2)c1Cc1ccc2ccccc2c1	This molecule has the following properties: Lipinski compliant; high DILI risk.	This molecule has the following properties: Lipinski compliant; reduced DILI risk.	Oc1noc(C2CCNCC2)c1Cc1ccc2ccccc2c1	Oc1noc(C2CCCNCC2)c1Cc1ccc2ccccc2c1O
39	Oc1noc(C2CCNCC2)c1Cc1ccc2ccccc2c1Br	This molecule has the following properties: Lipinski compliant; high DILI risk.	This molecule has the following properties: Lipinski compliant; reduced DILI risk.	Oc1noc(C2CCCNCC2)c1Cc1ccc2ccccc2c1Cl	Oc1noc(C2CCNCC2)c1Cc1ccc2ccccc2c1Cl
40	Oc1noc(C2CNCC2)c1Cc1ccc2cccc(Br)c2c1	This molecule has the following properties: Lipinski compliant; high DILI risk.	This molecule has the following properties: Lipinski compliant; reduced DILI risk.	Oc1noc(C2CCNCC2)c1Cc1ccc2cccc(Br)c2c1	Oc1noc(C2CNCC2)c1Cc1ccc2ccccClc2c1
41	CN1C(=O)CN=C(c2ccccc2)c2cc(Cl)ccc21	This molecule has the following properties: Lipinski compliant; very high CYP3A4 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP3A4 inhibition liability.	COC1=CC=C(C=NCC(=O)N2C)C2=CC(Cl)=C1	CN1C(=O)CN=C(c2ccccc2)c2cc(F)ccc21
42	C1=CC(=CC=C1N2C(=O)C3=C(N=N2)C4=CC=CC=C4N3)Cl	This molecule has the following properties: Lipinski compliant; high P-gp inhibition.	This molecule has the following properties: Lipinski compliant; reduced P-gp inhibition.	O=C1C2C=Nc3ccccc3C2=NN1c1ccc(Cl)cc1	C1=CC(=CC=C1N2C(=O)C3=C(N=N2)C4=CC=CC=C4N3)Br
43	Cc1ccc(N2CC(N3CCOCC3)=CC2=O)cc1	This molecule has the following properties: Lipinski compliant; high AMES risk.	This molecule has the following properties: Lipinski compliant; reduced AMES risk.	Cc1ccc(N2CC(N3CCNCC3)=CC2=O)cc1	Cc1ccc(N2CC(N3CCOCC3)C=C2)cc1
44	C1=CC(=O)N(CC2=NCCCO2)C=C1c1ccc(F)cc1	This molecule has the following properties: Lipinski compliant; moderate hERG liability.	This molecule has the following properties: Lipinski compliant; lower hERG liability.	O=C1C=C(N2CCOCC2)CN1c1ccc(F)cc1	C1=CC(=O)N(CC2=NCCCO2)C=C1c1cccClcc1
45	O=C1C=C(N2CCCC2)CN1c1ccc(Cl)cc1	This molecule has the following properties: Lipinski compliant; moderate CYP2C9 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP2C9 inhibition liability.	O=C1C=C(N2CCNCC2)CN1c1ccc(Cl)cc1	O=C1C=C(N2CCCC2)CN1c1cc(Cl)ccc1
46	O=C1C=C(N2CCCCC2)CN1c1ccc(Cl)cc1	This molecule has the following properties: Lipinski compliant; moderate DILI risk.	This molecule has the following properties: Lipinski compliant; reduced DILI risk.	O=C1C=C(N2CCCCCC2)CN1c1ccc(Cl)cc1	O=C1C=C(N2CCCCC2)CN1c1ccccc1
47	O=C1C=C(N2CCCC2)CN1c1ccc(Cl)cc1	This molecule has the following properties: Lipinski compliant; moderate DILI risk.	This molecule has the following properties: Lipinski compliant; reduced DILI risk.	CN1C=C(N2CCCC2)C(=O)C1c1ccc(Cl)cc1	O=C1C=C(N2CCCC2)CN1c1ccccc1
48	O=C1C=C(N2CCOCC2)CN1c1ccc(Cl)cc1	This molecule has the following properties: Lipinski compliant; moderate DILI risk.	This molecule has the following properties: Lipinski compliant; reduced DILI risk.	O=C1C=C(N2CCNCC2)CN1c1ccc(Cl)cc1	O=C1C=C(N2CCOCC2)CN1c1ccccc1
49	O=C1N(CCN2CC2)CN=C1Nc1ccc(OC)cc1	This molecule has the following properties: Lipinski compliant; very high CYP3A4 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP3A4 inhibition liability.	COc1ccc(N2CC(N3CCNCC3)=NC2=O)cc1	O=C1N(CCN2CC2)CN=C1Nc1cccc(C)c1
50	CCOC(=O)c1cnc2ccc(C)cc2c1O	This molecule has the following properties: Lipinski compliant; very high CYP2C9 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP2C9 inhibition liability.	CCOC(=O)c1cnc2ccc(C(F)(F)F)cc2c1O	CCOC(=O)c1cnc2ccc(C)cc2c1N
51	CCCOC(=O)c1cnc2cc(C)nn2c1O	This molecule has the following properties: Lipinski compliant; very low P-gp inhibition.	This molecule has the following properties: Lipinski compliant; reduced P-gp inhibition.	CCOC(=O)c1cnc2cc(C)nn2c1OC	CCCOC(=O)c1cnc2cc(C)nc2c1O
52	CCCNC(=O)c1cnc2ccc(Cc3ccccc3)cc2c1O	This molecule has the following properties: Lipinski compliant; moderate hepatotoxicity risk.	This molecule has the following properties: Lipinski compliant; reduced hepatotoxicity risk.	CCCNC(=O)c1cnc2ccc(Cc3ccccc3Cl)cc2c1O	CCCNC(=O)c1cnc2ccc(Cc3ccc4ccccc4c3)cc2c1O
53	CCCCNC(=O)c1cnc2ccc(C)cc2c1O	This molecule has the following properties: Lipinski compliant; very high CYP2C9 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP2C9 inhibition liability.	CCCCNC(=O)c1cnc2ccc(CC)cc2c1O	CCCCNC(=O)c1cnc2cc(CC)ccc2c1O
54	CCCNC(=O)c1cnc2ccc(C)cc2c1O	This molecule has the following properties: Lipinski compliant; very high CYP2C9 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP2C9 inhibition liability.	CCCNC(=O)c1cnc2ccc(CC)cc2c1O	CCCNC(=O)c1cnc2cc(C)ccc2c1O
55	CCCOC(=O)c1cnc2ccc(Cc3ccccc3)cc2c1O	This molecule has the following properties: Lipinski compliant; high P-gp inhibition.	This molecule has the following properties: Lipinski compliant; reduced P-gp inhibition.	CCCOC(=O)c1cnc2ccc(Cc3ccccc3)cc2c1N	CCCOC(=O)c1cnc2ccc(Cc3ccccc3)cc2c1
56	CCOC(=O)c1c[nH]c2ccc(Cc3ccccc3)cc2c1=O	This molecule has the following properties: Lipinski compliant; high hERG liability.	This molecule has the following properties: Lipinski compliant; lower hERG liability.	CC(=O)Nc1c[nH]c2ccc(Cc3ccccc3)cc2c1=O	CCOC(=O)c1c[nH]c2ccc(Cc3ccc(F)cc3)cc2c1=O
57	CCCCc1ccc2ncc(C(=O)OCC)c(O)c2c1	This molecule has the following properties: Lipinski compliant; high hERG liability.	This molecule has the following properties: Lipinski compliant; lower hERG liability.	CCCc1ccc2ncc(C(=O)OCC)c(O)c2c1	CCCCc1ccc2ncc(C(=O)OCC)c(Cl)c2c1
58	CCOC(=O)c1cnc2ccc(Br)cc2c1O	This molecule has the following properties: Lipinski compliant; very high CYP2C9 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP2C9 inhibition liability.	CC(=O)Oc1cnc2ccc(Br)cc2c1OC	CCOC(=O)c1cnc2cccClcc2c1O
59	CCCCOC(=O)c1cnc2ccccc2c1O	This molecule has the following properties: Lipinski compliant; high CYP2C9 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP2C9 inhibition liability.	C1=CC=C2C(=C1)C(=CN2)OCC(=O)O	CCCCOC(=O)c1cnc2scnc2c1O
60	CCOC(=O)c1cnc2ccccc2c1O	This molecule has the following properties: Lipinski compliant; very high CYP2C9 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP2C9 inhibition liability.	CC(=O)Oc1cnc2ccccc2c1O	CCOC(=O)c1cnc2scnc2c1O
61	CCc1ccc2ncc(C(=O)N)c(O)c2c1	This molecule has the following properties: Lipinski compliant; moderate hepatotoxicity risk.	This molecule has the following properties: Lipinski compliant; reduced hepatotoxicity risk.	CCc1ccc2ncc(C(=O)O)c(O)c2c1	CCc1ccc2ncc(C(=O)NC(=O)OC)c(O)c2c1
62	CCOc1ccc2ncc(C(=O)OC(C)C)c(O)c2c1	This molecule has the following properties: Lipinski compliant; moderate DILI risk.	This molecule has the following properties: Lipinski compliant; reduced DILI risk.	CCc1ccc2ncc(C(=O)OC(C)CC(C)C)c(O)c2c1	CCOc1ccc2ncc(C(=O)OCC(C)C)c(O)c2c1
63	CCc1ccc2ncc(C(=O)OC(C)C)c(O)c2c1	This molecule has the following properties: Lipinski compliant; very high CYP2C9 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP2C9 inhibition liability.	CCc1ccc2ncc(C(=O)OC)Cc(O)c2c1	CCc1ccc2ncc(C(=O)OC)nc2c1
64	CCc1ccc2ncc(C(=O)OC3CCCC3)c(O)c2c1	This molecule has the following properties: Lipinski compliant; high P-gp inhibition.	This molecule has the following properties: Lipinski compliant; reduced P-gp inhibition.	CNc1ccc2ncc(C(=O)OC3CCCC3)c(O)c2c1	CCc1ccc2ncc(C(=O)OC3CC(C)CC3)c(O)c2c1
65	CCc1ccc2ncc(C(=O)OCC(CC)CCO)c(O)c2c1	This molecule has the following properties: Lipinski compliant; moderate AMES risk.	This molecule has the following properties: Lipinski compliant; reduced AMES risk.	CCc1ccc2ncc(C(=O)OCC(CC)CC)c(O)c2c1	CCc1ccc2ncc(C(=O)OCC(C)CCO)c(O)c2c1
66	CCCCCOC(=O)c1cnc2ccc(CC)cc2c1O	This molecule has the following properties: Lipinski compliant; moderate hERG liability.	This molecule has the following properties: Lipinski compliant; lower hERG liability.	CCCC(=O)Oc1cnc2ccc(CC)cc2c1O	CCCCCOC(=O)c1cnc2ccccc2c1O
67	CCOC(=O)c1cc2ccccc2[nH]1	This molecule has the following properties: Lipinski compliant; moderate hERG liability.	This molecule has the following properties: Lipinski compliant; lower hERG liability.	CCc1ccc2ncc(C(=O)OCC(C)CC)c(O)c2c1	CCOC(=O)c1cc2cccc2[nH]1
68	CCc1ccc2ncc(C(=O)OCCC(C)C)c(O)c2c1	This molecule has the following properties: Lipinski compliant; very high CYP2C9 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP2C9 inhibition liability.	O=C(OCCCC(C)C)c1c(O)cc2nccc(CC)c2c1	CCc1ccc2ncc(C(=O)OCC(C)C)c(O)c2c1
69	CCCC(=O)c1cnc2ccc(CC)cc2c1O	This molecule has the following properties: Lipinski compliant; moderate AMES risk.	This molecule has the following properties: Lipinski compliant; reduced AMES risk.	CCCCOC(=O)c1cnc2ccc(CC)cc2c1O	CCCC(=O)c1cnc2ccccc2c1O
70	CCCOC(=O)c1cnc2ccc(CC)cc2c1O	This molecule has the following properties: Lipinski compliant; very high CYP2C9 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP2C9 inhibition liability.	CCCC(=O)c1cnc2ccc(C)cc2c1O	CCCOC(=O)c1cnc2ccc(C)cc2c1O
71	CCOC(=O)c1cnc2ccc(CC)cc2c1O	This molecule has the following properties: Lipinski compliant; very high CYP2C9 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP2C9 inhibition liability.	CC(=O)Oc1cnc2ccc(CCO)cc2c1O	CCOC(=O)c1cnc2cc(CC)ccc2c1O
72	CC(=O)N(Cc1ccccc1OC(C)C)c1ccc(Cl)cc1Oc1ccccc1	This molecule has the following properties: Lipinski compliant; high hERG liability.	This molecule has the following properties: Lipinski compliant; lower hERG liability.	CC(=O)N(Cc1ccccc1OC)c1ccc(Cl)cc1Oc1ccccc1	CC(=O)N(Cc1ccccc1OC(C)C)c1ccc(F)cc1Oc1ccccc1
73	CCC(C)N(C)C(=O)c1cc2ccccc2c(-c2ccccc2Cl)n1	This molecule has the following properties: Lipinski compliant; very high P-gp inhibition.	This molecule has the following properties: Lipinski compliant; reduced P-gp inhibition.	O=C(N(C)C(C)C)c1cc(-c2ccccc2Cl)c2ccccc2n1	CCC(C)N(C)C(=O)c1cc2ccccc2c(-c2ccc(F)cc2)n1
74	COc1ccc(OC)c(CN(C(C)=O)c2cc(F)ccc2OC)c1	This molecule has the following properties: Lipinski compliant; very high CYP2C9 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP2C9 inhibition liability.	COc1ccc(OC)c(CN(C(C)=O)c2cc(F)ccc2Oc2ccccc2)c1	COc1ccc(OC)c(CN(C(C)=O)c2ccClccc2OC)c1
75	COc1ccccc1CN(C(C)=O)c1ccc(Cl)cc1OC(F)(F)F	This molecule has the following properties: Lipinski compliant; high hERG liability.	This molecule has the following properties: Lipinski compliant; lower hERG liability.	COc1ccccc1CN(C(C)=O)c1ccc(Cl)cc1Oc1ccccc1	COc1ccccc1CN(C(C)=O)c1ccccc1OC(F)(F)F
76	CC(=O)N(Cc1ccccc1Oc1ccccc1)c1ccc(Cl)cc1OCCO	This molecule has the following properties: Lipinski compliant; high hERG liability.	This molecule has the following properties: Lipinski compliant; lower hERG liability.	CCOc1ccccc1CN(C(C)=O)c1ccc(Cl)cc1Oc1ccccc1	CC(=O)N(Cc1ccccc1Oc1ccccc1)c1ccc(F)cc1OCCO
77	O=C1NC(=O)C2=C1CNCC2	This molecule has the following properties: Lipinski compliant; very low CYP1A2 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP1A2 inhibition liability.	Oc1noc2c1CCNC2	O=C1NC(=O)C2=C1CNCC2O
78	NCCCC(=O)O	This molecule has the following properties: Lipinski compliant; moderate AMES risk.	This molecule has the following properties: Lipinski compliant; reduced AMES risk.	NCCCC(=O)C	NCCCC(=O)OC
79	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C(=O)OC)nc12	This molecule has the following properties: Lipinski compliant; very low CYP2C9 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP2C9 inhibition liability.	COC(=O)C1=NC2=C(N=C1)N(C1=NC=CN1)C1=C2N=CC=C1F	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C(=O)OC)nc12
80	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(-c3cccnc3)nc12	This molecule has the following properties: Lipinski compliant; high AMES risk.	This molecule has the following properties: Lipinski compliant; reduced AMES risk.	FC1=CC=CN=C1N1C=NC2=C1N=C(N1CCN=C1C1=CC=CN=C1)N=C2	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(-c3cccnc3)nc12
81	Cc1nc2c(CCCOCc3ccccc3)c(Cn3ccnc3-c3ncccc3F)ncn2n1	This molecule has the following properties: Lipinski compliant; high AMES risk.	This molecule has the following properties: Lipinski compliant; reduced AMES risk.	Cc1nc2c(CCCOCc3ccc(F)cc3)c(Cn3ccnc3-c3ncccc3Cl)ncn2n1	Cc1nc2c(CCCOCc3ccccc3)c(Cn3ccnc3-c3ncnc3F)ncn2n1
82	O=C(Nc1ncnc2nc(F)ccc12)c1ccncc1	This molecule has the following properties: Lipinski compliant; very high CYP1A2 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP1A2 inhibition liability.	Cc1nc2c(CCO)c(Cn3ccnc3-c3ncccc3F)ncn2n1	O=C(Nc1ncnc2nc(C)ccc12)c1ccncc1
83	Cc1nc2c(CCCC[N+](=O)[O-])c(Cn3ccnc3-c3ncccc3F)ncn2n1	This molecule has the following properties: Lipinski compliant; high DILI risk.	This molecule has the following properties: Lipinski compliant; reduced DILI risk.	Cc1nc2c(CCCCl)c(Cn3ccnc3-c3ncccc3F)ncn2n1	Cc1nc2c(CCCC[N+](=O)[O-])c(Cn3ccnc3-c3ncnc3F)ncn2n1
84	Cc1nc2c(CCF)c(Cn3ccnc3-c3ncccc3F)ncn2n1	This molecule has the following properties: Lipinski compliant; low P-gp inhibition.	This molecule has the following properties: Lipinski compliant; reduced P-gp inhibition.	O=C(NCc1nc2c(CCF)c(Cn3ccnc3-c3ncccc3F)ncn2n1)c1ccco1	Cc1nc2c(CCF)c(Cn3ccnc3-c3ncnc3F)ncn2n1
85	CCc1c(Cn2ccnc2-c2ncccc2Cl)ncn2ncnc12	This molecule has the following properties: Lipinski compliant; high AMES risk.	This molecule has the following properties: Lipinski compliant; reduced AMES risk.	CCc1c(Cn2ccnc2-c2ncccc2F)ncn2ncnc12	CCc1c(Cn2ccnc2-c2ncccc2)ncn2ncnc12
86	Fc1ccc(Cn2ccnc2-c2cccc(C(F)(F)F)n2)nc1	This molecule has the following properties: Lipinski compliant; high hERG liability.	This molecule has the following properties: Lipinski compliant; lower hERG liability.	CCCc1c(Cn2ccnc2-c2cccc(C(F)(F)F)n2)ncn2ncnc12	Fc1ccc(Cn2ccnc2-c2cccc(C(F)(F)F)n2)nc1
87	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C(N)=O)nc12	This molecule has the following properties: Lipinski compliant; high DILI risk.	This molecule has the following properties: Lipinski compliant; reduced DILI risk.	CCCC1=C(Cn2ccnc2-c2ncccc2F)N=C2N=C(NC=O)N=C12	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C(N)=O)nc12
88	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C(=O)OCC)nc12	This molecule has the following properties: Lipinski compliant; high DILI risk.	This molecule has the following properties: Lipinski compliant; reduced DILI risk.	CCCC1=C(Cn2ccnc2-c2ncccc2F)N=CN2C(=O)OCCN=C12	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C(=O)O)nc12
89	CCCc1c(Cn2cc(Cl)nc2-c2ncccc2F)ncn2ncnc12	This molecule has the following properties: Lipinski compliant; moderate DILI risk.	This molecule has the following properties: Lipinski compliant; reduced DILI risk.	FC1=CC=CC2=C1N=C(N1CCN(CC)CC1)N=C2	CCCc1c(Cn2cc(Cl)nc2-c2ncccn2F)ncn2ncnc12
90	CCCc1c(Cn2ccnc2-c2ncccc2C#N)ncn2nc(C)nc12	This molecule has the following properties: Lipinski compliant; moderate hERG liability.	This molecule has the following properties: Lipinski compliant; lower hERG liability.	CCOc1c(Cn2ccnc2-c2ncccc2C#N)ncn2nc(C)nc12	CCCc1c(Cn2ccnc2-c2ncccc2C#N)ncn2nc(C)nc12
91	CCCc1c(Cn2ccnc2-c2cccc(C#N)n2)ncn2nc(COC(C)C)nc12	This molecule has the following properties: Lipinski compliant; high hERG liability.	This molecule has the following properties: Lipinski compliant; lower hERG liability.	CCCC1=C(Cn2ccnc2-c2cccc(C#N)n2)N=C3N=C(COC(C)C)N=C1N3	CCCc1c(Cn2ccnc2-c2cccc(C#N)n2)ncn2nc(COC)nc12
92	CCOc1c(Cn2ccnc2-c2ncccc2F)ncn2ncnc12	This molecule has the following properties: Lipinski compliant; high AMES risk.	This molecule has the following properties: Lipinski compliant; reduced AMES risk.	FC1=CC=C(C=N1)C1=CN=C(C2=CNC3=NC=CN=C23)N1	CCOc1c(Cn2ccnc2-c2nc(C)cccc2F)ncn2ncnc12
93	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(N)nc12	This molecule has the following properties: Lipinski compliant; high AMES risk.	This molecule has the following properties: Lipinski compliant; reduced AMES risk.	CN(C)c1c(Cn2ccnc2-c2ncccc2F)ncn2nc(N)nc12	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(N)nc12
94	CCCc1c(Cn2ccnc2-c2cccc(F)n2)ncn2nc(C(C)(C)O)nc12	This molecule has the following properties: Lipinski compliant; very high CYP1A2 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP1A2 inhibition liability.	CCCC1=C(Cn2ccnc2-c2cccc(F)n2)N=C3N=C(C(C)(C)O)N=C1N3	CCCc1c(Cn2ccnc2-c2ccccCl)ncc2nc(C(C)(C)O)nc12
95	CN(C)c1ccc(Cn2ccnc2-c2cccc(C#N)n2)nc1	This molecule has the following properties: Lipinski compliant; high hERG liability.	This molecule has the following properties: Lipinski compliant; lower hERG liability.	CCCc1c(Cn2ccnc2-c2cccc(C#N)n2)ncn2nc(COC)nc12	CN(C)c1ccc(Cn2ccnc2-c2cccc(C#N)n2)nc1
96	Cc1nc2c(CCOCc3ccccc3)c(Cn3ccnc3-c3ncncc3F)ncn2n1	This molecule has the following properties: Lipinski compliant; very high CYP1A2 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP1A2 inhibition liability.	Cc1nc2c(CCOCc3ccccc3)c(Cn3ccnc3-c3ncccc3F)ncn2n1	Cc1nc2c(CCOCc3ccccc3)c(Cn3ccnc3-c3ncncc3F)ncn2n1
97	Cc1nc2c(CCCO)c(Cn3ccnc3-c3ncccc3F)ncn2n1	This molecule has the following properties: Lipinski compliant; high DILI risk.	This molecule has the following properties: Lipinski compliant; reduced DILI risk.	Cc1nc2c(CCCN)c(Cn3ccnc3-c3ncccc3F)ncn2n1	Cc1nc2c(CCCO)c(Cn3ccnc3-c3ncnc3F)ncn2n1
98	Cc1nc2c(CCCF)c(Cn3ccnc3-c3ncccc3F)ncn2n1	This molecule has the following properties: Lipinski compliant; low P-gp inhibition.	This molecule has the following properties: Lipinski compliant; reduced P-gp inhibition.	CC1=NC2=C(N=CN2N1)C3=CC=CN=C3F	Cc1nc2c(CCCF)c(Cn3ccnc3-c3ncnc3F)ncn2n1
99	FCCCc1c(Cn2ccnc2-c2ncncc2F)ncn2ncnc12	This molecule has the following properties: Lipinski compliant; very high CYP1A2 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP1A2 inhibition liability.	FCCCc1c(Cn2ccnc2-c2ncccc2F)ncn2ncnc12	FCCCc1c(Cn2ccnc2-c2ncncc2F)ncn2ncnc12
100	N#Cc1cccnc1-c1nccn1Cc1ncn2ncnc2c1CCCF	This molecule has the following properties: Lipinski compliant; high hERG liability.	This molecule has the following properties: Lipinski compliant; lower hERG liability.	N#Cc1cccnc1-c1nccn1Cc1ncn2ncnc2c1CC	N#Cc1cccnc1-c1nccn1Cc1ncn2ncnc2c1CCCN
101	CN(C)Cc1cccc(-c2nccn2Cc2ncn3ncnc3c2CCCF)n1	This molecule has the following properties: Lipinski compliant; high hERG liability.	This molecule has the following properties: Lipinski compliant; lower hERG liability.	N#Cc1cccc(-c2nccn2Cc2ncn3ncnc3c2CCCF)n1	CN(C)Cc1cccc(-c2nccn2Cc2ncn3ncnc3c2CCCN)n1
102	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C#N)nc12	This molecule has the following properties: Lipinski compliant; very high CYP1A2 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP1A2 inhibition liability.	CN(C)c1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C#N)N12	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C)nc12
103	CCOc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C)nc12	This molecule has the following properties: Lipinski compliant; high P-gp inhibition.	This molecule has the following properties: Lipinski compliant; reduced P-gp inhibition.	CCNc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C)nc12	CCOc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C)nc12
104	CCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C)nc12	This molecule has the following properties: Lipinski compliant; high CYP1A2 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP1A2 inhibition liability.	CNc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(N)nc12	CCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C)nc12
105	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(OCC)nc12	This molecule has the following properties: Lipinski compliant; low P-gp inhibition.	This molecule has the following properties: Lipinski compliant; reduced P-gp inhibition.	CCCC1=C(Cn2ccnc2-c2ncccc2F)N=C2N=C(OCC)N=C12	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(OCCCC)nc12
106	CCCc1c(Cn2ccnc2-c2cccc(F)n2)ncn2nc(COCC)nc12	This molecule has the following properties: Lipinski compliant; high CYP1A2 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP1A2 inhibition liability.	CCOCCn1nc2nc(Cn3ccnc3-c3cccc(F)n3)nc2n1Cc1ccco1	CCCc1c(Cn2ccnc2-c2ccccCl)ncc2nc(COCC)nc12
107	CCC(O)c1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C)nc12	This molecule has the following properties: Lipinski compliant; high AMES risk.	This molecule has the following properties: Lipinski compliant; reduced AMES risk.	CC(C)(O)c1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C)nc12	CCC(O)c1c(Cn2ccnc2-c2ncc(c2)cc2F)ncn2nc(C)nc12
108	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(CO)nc12	This molecule has the following properties: Lipinski compliant; high AMES risk.	This molecule has the following properties: Lipinski compliant; reduced AMES risk.	CN1CCN(CC1)c1ncn2nc(CO)nc2c1-c1ncccc1F	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(CO)nc12
109	O=C(Nc1ncnc2nc(C)c(N3CCOCC3)n12)c1ccc(F)cc1	This molecule has the following properties: Lipinski compliant; high P-gp inhibition.	This molecule has the following properties: Lipinski compliant; reduced P-gp inhibition.	C/C=C/c1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C)nc12	O=C(Nc1ncnc2nc(C)c(N3CCOCC3)n12)c1ccccc1
110	CCCc1c(Cn2ccnc2-c2cccc(F)n2)ncn2c(C)c(C)nc12	This molecule has the following properties: Lipinski compliant; moderate DILI risk.	This molecule has the following properties: Lipinski compliant; reduced DILI risk.	CCCC1=C(Cn2ccnc2-c2cccc(F)n2)N=C3N=C(C)C(C)N=C13	CCCc1c(Cn2ccnc2-c2ccccCl)ncc2c(C)c(C)nc12
111	CCCCn1cnc2nc(CC)c(-c3cccc(F)n3)nc12	This molecule has the following properties: Lipinski compliant; high AMES risk.	This molecule has the following properties: Lipinski compliant; reduced AMES risk.	CCCc1c(Cn2ccnc2-c2cccc(F)n2)ncn2cc(CC)nc12	CCCCn1cnc2nc(CC)c(-c3cc(F)ccc3)n12
112	CCCc1c(Cn2ccnc2-c2cccc(F)n2)ncn2c(C(=O)OCC)cnc12	This molecule has the following properties: Lipinski compliant; moderate DILI risk.	This molecule has the following properties: Lipinski compliant; reduced DILI risk.	CCCC1=C(Cn2ccnc2-c2cccc(F)n2)N=CN2C(=O)OCC=CN=C12	CCCc1c(Cn2ccnc2-c2ccccn2)ncn2c(C(=O)OCC)cnc12
113	CCCc1c(Cn2ccnc2-c2cccc(F)n2)ncn2cc(C(=O)OCC)nc12	This molecule has the following properties: Lipinski compliant; high DILI risk.	This molecule has the following properties: Lipinski compliant; reduced DILI risk.	CCCC1=C(Cn2ccnc2-c2cccc(F)n2)N=C(N2C=C(C(=O)OCC)C=C2)N1	CCCc1c(Cn2ccnc2-c2ccccCl)nccn2cc(C(=O)OCC)nc12
114	CCCc1c(Cn2ccnc2-c2cccc(F)n2)ncn2cc(C)nc12	This molecule has the following properties: Lipinski compliant; high AMES risk.	This molecule has the following properties: Lipinski compliant; reduced AMES risk.	CCCC1=C(Cn2ccnc2-c2cccc(F)n2)NC(=N2)C1=NCC2	CCCc1c(Cn2ccnc2-c2ccccCl)ncc2cc(C)nc12
115	CCCc1c(Cn2ccnc2-c2cccc(F)n2)ncn2cc(C(F)(F)F)nc12	This molecule has the following properties: Lipinski compliant; high P-gp inhibition.	This molecule has the following properties: Lipinski compliant; reduced P-gp inhibition.	C(F)(F)(F)c1nc2ncn(C)c2nc2cc(F)ccc2n1	CCCc1c(Cn2ccnc2-c2ccccCl)ncc2cc(C(F)(F)F)nc12
116	CCCc1c(Cn2ccnc2-c2ccccn2)ncn2ccnc12	This molecule has the following properties: Lipinski compliant; high AMES risk.	This molecule has the following properties: Lipinski compliant; reduced AMES risk.	c1cc(CN2C=NC=C2)nc2cccn12	CCCc1c(Cn2ccnc2-c2cccn2)ncn2ccnc12
117	CCOc1c(Cn2ccnc2-c2ccccn2)ncn2cc(C(F)(F)F)nc12	This molecule has the following properties: Lipinski compliant; moderate hERG liability.	This molecule has the following properties: Lipinski compliant; lower hERG liability.	CCc1c(Cn2ccnc2-c2ccccn2)ncn2cc(C(F)(F)F)nc12	CCOc1c(Cn2ccnc2-c2ccccn2)ncn2cc(C(F)(F)F)nc12
118	CCOc1c(Cn2ccnc2-c2c(F)cccc2F)ncn2ccnc12	This molecule has the following properties: Lipinski compliant; high hERG liability.	This molecule has the following properties: Lipinski compliant; lower hERG liability.	CCCc1c(Cn2ccnc2-c2c(F)cccc2F)ncn2ccnc12	CCOc1c(Cn2ccnc2-c2c(F)cccc2F)ncn2ccnc12
119	O=C(Nc1nc2cc(F)ccc2[nH]1)c1ccc(F)cc1	This molecule has the following properties: Lipinski compliant; high hERG liability.	This molecule has the following properties: Lipinski compliant; lower hERG liability.	CCCc1c(Cn2ccnc2-c2c(F)cccc2F)ncn2cc(C(F)(F)F)nc12	O=C(Nc1nc2ccc(F)cc2[nH]1)c1cc(F)cc2cc1c1ccccc12
120	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2ccnc12	This molecule has the following properties: Lipinski compliant; moderate hERG liability.	This molecule has the following properties: Lipinski compliant; lower hERG liability.	FC1=CC=CN=C1C1=NCC2=C1N=CN=C2Cn1cncc1	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2ccnc12
121	CCCc1c(Cn2ccnc2-c2ccccn2)ncn2cc(-c3ccccc3)nc12	This molecule has the following properties: Lipinski compliant; moderate hepatotoxicity risk.	This molecule has the following properties: Lipinski compliant; reduced hepatotoxicity risk.	CN(C)c1c(Cn2ccnc2-c2ccccn2)ncn2cc(-c3ccccc3)nc12	CCCc1c(Cn2ccnc2-c2ccccn2)ncn2cc(-c3ccc(F)cc3)nc12
122	CCCc1c(Cn2ccnc2-c2cccc(F)n2)ncn2nc(C)nc12	This molecule has the following properties: Lipinski compliant; moderate P-gp inhibition.	This molecule has the following properties: Lipinski compliant; reduced P-gp inhibition.	CCCC1=C(Cn2ccnc2-c2cccc(F)n2)NC(=N1)N1C=NC=C1	CCCc1c(Cn2ccnc2-c2ccccCl)ncc2nc(C)nc12
123	CCCc1c(Cn2ccnc2-c2cccc(F)n2)ncn2ncnc12	This molecule has the following properties: Lipinski compliant; high AMES risk.	This molecule has the following properties: Lipinski compliant; reduced AMES risk.	FC1=CC=C(N=C1)C1=CC2=NC=NC(N3CCNCC3)=C2N=C1	CCCc1c(Cn2ccnc2-c2ccccCl)ncc2ncnc12
124	C=CCc1c(Cn2ccnc2-c2ncccc2F)ncn2ncnc12	This molecule has the following properties: Lipinski compliant; high AMES risk.	This molecule has the following properties: Lipinski compliant; reduced AMES risk.	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2ncnc12	C=CCc1c(Cn2ccnc2-c2ncc(c2)ccF)ncn2ncnc12
125	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C(C)O)nc12	This molecule has the following properties: Lipinski compliant; high DILI risk.	This molecule has the following properties: Lipinski compliant; reduced DILI risk.	CCCC1=C(Cn2ccnc2-c2ncccc2F)N=C2N=C(NC(C)O)N=C12	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C)nc12
126	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C(F)(F)F)nc12	This molecule has the following properties: Lipinski compliant; moderate CYP1A2 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP1A2 inhibition liability.	C[C@H](O)c1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C(F)(F)F)nc12	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C(F)(F)F)nc12
127	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(COC)nc12	This molecule has the following properties: Lipinski compliant; high CYP2C9 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP2C9 inhibition liability.	CCCC1=C(N=C2N=C(N=C12)COC)N=C1C=CN=C1C1=CC=CN1F	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(CO)nc12
128	CCCc1c(Cn2ccnc2-c2cccc(F)n2)ncn2nc(COC)nc12	This molecule has the following properties: Lipinski compliant; high CYP1A2 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP1A2 inhibition liability.	CCCC1=C(Cn2ccnc2-c2cccc(F)n2)NC(=O)N2NC(=O)NC12	CCCc1c(Cn2ccnc2-c2ccccCl)n(cn1)COC
129	CCCc1c(Cn2ccnc2-c2cccc(F)n2)ncn2nc(C3CCC3)nc12	This molecule has the following properties: Lipinski compliant; very high P-gp inhibition.	This molecule has the following properties: Lipinski compliant; reduced P-gp inhibition.	CCCC1=C(Cn2ccnc2-c2cccc(F)n2)N=C3N=C(N=C13)C4CC4	CCCc1c(Cn2ccnc2-c2ccccn2)ncn2nc(C3CCC3)nc12
130	Cc1c(Cn2ccnc2-c2ccccn2)ncn2ncnc12	This molecule has the following properties: Lipinski compliant; high AMES risk.	This molecule has the following properties: Lipinski compliant; reduced AMES risk.	CCCc1c(Cn2ccnc2-c2ccccn2)ncn2ncnc12	Cc1c(Cn2ccnc2-c2ccccn2)ncn2ncnc12
131	CCCc1c(Cn2ccnc2-c2cc(F)ccc2F)ncn2nc(C)nc12	This molecule has the following properties: Lipinski compliant; very high P-gp inhibition.	This molecule has the following properties: Lipinski compliant; reduced P-gp inhibition.	CCCC1=C(Cn2ccnc2-c2cc(F)ccc2F)N=C3N=C(C)N=C1N3	CCCc1c(Cn2ccnc2-c2cc(F)ccc2F)ncn2nc(C)nc12
132	CCCc1c(Cn2ccnc2-c2cccc(OC)n2)ncn2ncnc12	This molecule has the following properties: Lipinski compliant; very high CYP1A2 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP1A2 inhibition liability.	CN(C)c1cc(OC)ccc1-c1cncn1C1CCCN1Cc1ccncn1	CCCc1c(Cn2ccnc2-c2ccccn2)ncn2ncnc12
133	CCCc1c(Cn2ccnc2-c2nccs2)ncn2nc(C)nc12	This molecule has the following properties: Lipinski compliant; high CYP2D6 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP2D6 inhibition liability.	Cc1nc2c(ncn2-c2nc(CC)cs2)n1Cn1ccnc1-c1ncc(C)s1	CCCc1c(Cn2ccnc2-c2nc(cs2)C)ncn2nc(C)nc12
134	CCCc1c(Cn2ccnc2-c2ccccn2)ncn2nc(C)nc12	This molecule has the following properties: Lipinski compliant; high AMES risk.	This molecule has the following properties: Lipinski compliant; reduced AMES risk.	CCCC1=C(Cn2ccnc2-c2ccccn2)nc2nc(C)nc12	CCCc1c(Cn2ccnc2-c2cccn2)ncn2nc(C)nc12
135	O=C(Nc1cccc(O)c1)c1cccnc1	This molecule has the following properties: Lipinski compliant; very high CYP1A2 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP1A2 inhibition liability.	CCCc1c(Cn2ccnc2-c2cccc(O)n2)ncn2ncnc12	O=C(Nc1cccc(O)c1)c1cncnc1
136	CCCc1c(Cn2ccnc2-c2cccs2)ncn2ncnc12	This molecule has the following properties: Lipinski compliant; very high CYP1A2 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP1A2 inhibition liability.	CN1CCN(CC1)c1c(Cn2ccnc2-c2cccs2)ncn2ncnc12	CCCc1c(Cn2ccnc2-c2cccs2)ncn2ncnc12
137	CCCc1c(Cn2ccnc2-c2cccnn2)ncn2nc(C)nc12	This molecule has the following properties: Lipinski compliant; very high CYP1A2 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP1A2 inhibition liability.	CN(C)c1c(Cn2ccnc2-c2cccnn2)ncn2nc(N)nc12	CCCc1c(Cn2ccnc2-c2cccnn2)ncn2nc(C)nc12
138	FC1=CC=C(C2=NC=C(N3CC3)N=C2)C=C1	This molecule has the following properties: Lipinski compliant; high P-gp inhibition.	This molecule has the following properties: Lipinski compliant; reduced P-gp inhibition.	CCc1c(Cn2ccnc2-c2cc(F)ccc2F)ncn2ncnc12	FC1=CC=C(C2=NC=C(N3CC3)S=C2)C=C1
139	CCc1c(Cn2ccnc2-c2ccc(F)cc2F)ncn2nc(C)nc12	This molecule has the following properties: Lipinski compliant; high DILI risk.	This molecule has the following properties: Lipinski compliant; reduced DILI risk.	CCc1c(Cn2ccnc2-c2cc(F)ccc2F)ncn2nc(C)nc12	CCc1c(Cn2ccnc2-c2ccc(F)cc2F)ncn2nc(C)nc12
140	CCc1c(Cn2ccnc2-c2cc(F)ccc2C)ncn2ncnc12	This molecule has the following properties: Lipinski compliant; high AMES risk.	This molecule has the following properties: Lipinski compliant; reduced AMES risk.	FC1=CC=C(C=C1)C1=CC2=NC=NC(N3CCNCC3)=C2N=C1	CCc1c(Cn2ccnc2-c2ccccc2C)ncn2ncnc12
141	FC(F)(F)COCCn1nc2nc(Cn3ccnc3-c3ncccc3F)nc2n1CC	This molecule has the following properties: Lipinski compliant; high hERG liability.	This molecule has the following properties: Lipinski compliant; lower hERG liability.	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(COCC(F)(F)F)nc12	FC(F)(F)COCCn1nc2nc(Cn3ccnc3-c3nc4ccccc4c3F)nc2n1CC
142	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(Cl)nc12	This molecule has the following properties: Lipinski compliant; moderate P-gp inhibition.	This molecule has the following properties: Lipinski compliant; reduced P-gp inhibition.	CCCC1=C(Cn2ccnc2-c2ncccc2F)N=CN2C(=NC12)Cl	CCCc1c(Cn2ccnc2-c2ncccs2)ncn2nc(Cl)nc12
143	CCCC1=C(Cn2ccnc2-c2ncccc2F)ncn2nc(CCF)nc12	This molecule has the following properties: Lipinski compliant; moderate P-gp inhibition.	This molecule has the following properties: Lipinski compliant; reduced P-gp inhibition.	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(CC(F)(F)F)nc12	CCCC1=C(Cn2ccnc2-c2ncccc2F)ncn2nc(C)nc12
144	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(-c3nccs3)nc12	This molecule has the following properties: Lipinski compliant; moderate hERG liability.	This molecule has the following properties: Lipinski compliant; lower hERG liability.	CCCC1=C(Cn2ccnc2-c2ncccc2F)N=C(N2N=C(C3=NC=CS3)C1=O)N2	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(-c3nc(cs3)C(F)(F)F)nc12
145	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(N(CCC)CCC)nc12	This molecule has the following properties: Lipinski compliant; very high CYP1A2 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP1A2 inhibition liability.	CN(C)CCN1C(=O)C2=CC=CC=C2N=C1N1CCN(C)CC1	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(N(CCC)CCC)nc12
146	CCCc1c(Cn2ccnc2-c2cccc(C#N)n2)ncn2nc(COCC)nc12	This molecule has the following properties: Lipinski compliant; very high CYP2C9 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP2C9 inhibition liability.	CN(C)CCc1c(Cn2ccnc2-c2cccc(C#N)n2)ncn2nc(COC)nc12	CCCc1c(Cn2ccnc2-c2cccc(C#N)n2)ncn2nc(CO)nc12
147	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(COCC)nc12	This molecule has the following properties: Lipinski compliant; high AMES risk.	This molecule has the following properties: Lipinski compliant; reduced AMES risk.	CCCC1=C(Cn2ccnc2-c2ncccc2F)N=CN2C(=NC1=O)N(C)CC2	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(COC)nc12
148	CCCc1c(Cn2ccnc2-c2cccc(C#N)n2)ncn2nc(C)nc12	This molecule has the following properties: Lipinski compliant; high DILI risk.	This molecule has the following properties: Lipinski compliant; reduced DILI risk.	CN(C)c1ccc(Cn2ccnc2-c2cccc(C#N)n2)cc1	CCCc1c(Cn2ccnc2-c2cccc(C#N)n2)ncn2nc(C)nc12
149	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(COC(C)C)nc12	This molecule has the following properties: Lipinski compliant; high DILI risk.	This molecule has the following properties: Lipinski compliant; reduced DILI risk.	CCCC1=C(Cn2ccnc2-c2ncccc2F)N=C3N=C(COC(C)C)N=C1N3	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(COC(C)C)nc12
150	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(CC)nc12	This molecule has the following properties: Lipinski compliant; moderate P-gp inhibition.	This molecule has the following properties: Lipinski compliant; reduced P-gp inhibition.	CCCC1=C(Cn2ccnc2-c2ncccc2F)N=C2N=C(NC12)C	CCCc1c(Cn2ccnc2-c2ncc(c2)ccF)ncn2nc(CC)nc12
151	FC1=CC=C(C2=NC3=C(N=CN3C3CCNCC3)C(=N2)N2C=NC=C2)C=C1	This molecule has the following properties: Lipinski compliant; high hERG liability.	This molecule has the following properties: Lipinski compliant; lower hERG liability.	CCc1c(Cn2ccnc2-c2cc(F)ccc2C)ncn2nc(C)nc12	FC1=CC=C(C2=NC3=C(N=CN3C3CCNCC3)C(=N2)N2C=NC=C2)C=C1
152	CCCc1c(Cn2ccnc2-c2cccc(F)n2)nc(C)n2nc(C)nc12	This molecule has the following properties: Lipinski compliant; very high P-gp inhibition.	This molecule has the following properties: Lipinski compliant; reduced P-gp inhibition.	CCCC1=C(Cn2ccnc2-c2cccc(F)n2)N=C(N2C=NC=C12)C	CCCc1c(Cn2ccnc2-c2ccccCl)nnc(C)n2nc(C)nc12
153	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C(F)F)nc12	This molecule has the following properties: Lipinski compliant; high AMES risk.	This molecule has the following properties: Lipinski compliant; reduced AMES risk.	CCCC1=C(Cn2ccnc2-c2ncccc2F)N=C3N=C(N=C13)C(F)(F)F	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C)nc12
154	CCCc1c(Cn2ccnc2-c2cccc(F)n2)nc(C)n2nc(CC)nc12	This molecule has the following properties: Lipinski compliant; very high P-gp inhibition.	This molecule has the following properties: Lipinski compliant; reduced P-gp inhibition.	CCCC1=C(Cn2ccnc2-c2cccc(F)n2)N=C(N2C=C(NCC)C=C2)N1	CCCc1c(Cn2ccnc2-c2ccccCl)n3nc(CC)nc3nc12
155	CNc1nc2c(CN)c(Cn3ccnc3-c3cc(F)ccc3N)ncn2n1	This molecule has the following properties: Lipinski compliant; high AMES risk.	This molecule has the following properties: Lipinski compliant; reduced AMES risk.	CCc1nc2c(CC)c(Cn3ccnc3-c3cc(F)ccc3C)ncn2n1	CNc1nc2c(CN)c(CN3CCNc3-c3cc(F)ccc3N)ncn2n1
156	CC[C@H](O)c1c(Cn2ccnc2-c2cccc(F)n2)ncn2nc(C)nc12	This molecule has the following properties: Lipinski compliant; high DILI risk.	This molecule has the following properties: Lipinski compliant; reduced DILI risk.	CCC(O)c1c(Cn2ccnc2-c2cccc(F)n2)ncn2nc(C)nc12	CC[C@H](O)c1c(Cn2ccnc2-c2ccc(F)nc2)ncn2nc(C)nc12
157	COCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(C)nc12	This molecule has the following properties: Lipinski compliant; high AMES risk.	This molecule has the following properties: Lipinski compliant; reduced AMES risk.	CC(=O)Nc1ncnc2nc(C)nc(COc3cc(Cn4ccnc4-c4ncccc4F)cn12)c3	COCc1c(Cn2ccnc2-c2ncccn2F)ncn2nc(C)nc12
158	CCCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(CCOC3CCCC3)nc12	This molecule has the following properties: Lipinski compliant; high hERG liability.	This molecule has the following properties: Lipinski compliant; lower hERG liability.	CCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(COC3CCCC3)nc12	CCCCc1c(Cn2ccnc2-c2ncccc2F)ncn2nc(CCOC3CCCC3)nc12
159	CCCCc1c(Cn2ccnc2-c2cccc(F)n2)ncn2ccnc12	This molecule has the following properties: Lipinski compliant; high hERG liability.	This molecule has the following properties: Lipinski compliant; lower hERG liability.	CCCc1c(Cn2ccnc2-c2cccc(F)n2)ncn2ccnc12	CCCCc1c(Cn2ccnc2-c2ccccCl)ncc2ccnc12
160	CCCc1c(Cn2ccnc2-c2cccc(F)n2)nc(C)n2ccnc12	This molecule has the following properties: Lipinski compliant; high hERG liability.	This molecule has the following properties: Lipinski compliant; lower hERG liability.	CN(C)c1c(Cn2ccnc2-c2cccc(F)n2)nc(C)n2ccnc12	CCCc1c(Cn2ccnc2-c2ccccCl)n3ccnc3nc12
161	CCCc1c(Cn2ccnc2-c2cccc(F)n2)ncn2cc(C#N)nc12	This molecule has the following properties: Lipinski compliant; high hERG liability.	This molecule has the following properties: Lipinski compliant; lower hERG liability.	C#Cc1c(Cn2ccnc2-c2cccc(F)n2)ncn2cc(C#N)nc12	CCCc1c(Cn2ccnc2-c2ccccCl)ncc2cc(C#N)nc12
162	CCCc1c(Cn2ccnc2-c2cccc(F)n2)ncn2c(C#N)cnc12	This molecule has the following properties: Lipinski compliant; very high CYP2C9 inhibition.	This molecule has the following properties: Lipinski compliant; reduced CYP2C9 inhibition liability.	O=C(Nc1ncnc2nc(C#N)cnc12)c1cccc(F)n1	CCCc1c(Cn2ccnc2-c2ccccCl)n(cn12)c2C#N
